BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 14729934)

  • 1. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
    Dannaoui E; Meletiadis J; Tortorano AM; Symoens F; Nolard N; Viviani MA; Piens MA; Lebeau B; Verweij PE; Grillot R; And The Ebga Network
    J Med Microbiol; 2004 Feb; 53(Pt 2):129-134. PubMed ID: 14729934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
    Paterson PJ; Seaton S; Prentice HG; Kibbler CC
    J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
    Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
    J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus.
    Dannaoui E; Borel E; Persat F; Monier MF; Piens MA; Network E
    J Med Microbiol; 1999 Dec; 48(12):1087-1093. PubMed ID: 10591162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis.
    Moosa MY; Alangaden GJ; Manavathu E; Chandrasekar PH
    J Antimicrob Chemother; 2002 Jan; 49(1):209-13. PubMed ID: 11751792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey.
    Özmerdiven GE; Ak S; Ener B; Ağca H; Cilo BD; Tunca B; Akalın H
    J Infect Chemother; 2015 Aug; 21(8):581-6. PubMed ID: 26048062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired itraconazole resistance in Aspergillus fumigatus.
    Dannaoui E; Borel E; Monier MF; Piens MA; Picot S; Persat F
    J Antimicrob Chemother; 2001 Mar; 47(3):333-40. PubMed ID: 11222566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole.
    Silvanose CD; Bailey TA; Di Somma A
    Vet Rec; 2006 Aug; 159(9):282-4. PubMed ID: 16946311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
    Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
    Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole.
    Beernaert LA; Pasmans F; Van Waeyenberghe L; Dorrestein GM; Verstappen F; Vercammen F; Haesebrouck F; Martel A
    Antimicrob Agents Chemother; 2009 May; 53(5):2199-201. PubMed ID: 19258265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA; Morrissey G; Morrissey J; Denning DW
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
    Wang HC; Hsieh MI; Choi PC; Wu CJ
    J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of medium composition on static and cidal activity of amphotericin B, itraconazole, voriconazole, posaconazole and terbinafine against Aspergillus fumigatus: a multicenter study.
    Tortorano AM; Dannaoui E; Meletiadis J; Mallie M; Viviani MA; Piens MA; Rigoni AL; Bastide JM; Grillot R;
    J Chemother; 2002 Jun; 14(3):246-52. PubMed ID: 12120878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.
    Manavathu EK; Abraham OC; Chandrasekar PH
    Clin Microbiol Infect; 2001 Mar; 7(3):130-7. PubMed ID: 11318811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
    Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
    J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.
    Gregson L; Goodwin J; Johnson A; McEntee L; Moore CB; Richardson M; Hope WW; Howard SJ
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5778-80. PubMed ID: 24041890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients.
    Negri CE; Gonçalves SS; Sousa ACP; Bergamasco MD; Martino MDV; Queiroz-Telles F; Aquino VR; Castro PTO; Hagen F; Meis JF; Colombo AL
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28893772
    [No Abstract]   [Full Text] [Related]  

  • 19. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility.
    Mortensen KL; Johansen HK; Fuursted K; Knudsen JD; Gahrn-Hansen B; Jensen RH; Howard SJ; Arendrup MC
    Eur J Clin Microbiol Infect Dis; 2011 Nov; 30(11):1355-63. PubMed ID: 21541671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
    J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.